Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02030977

The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis

The Effects of Resveratrol Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis

Sponsor: Dr Azita Hekmatdoost

Conditions Non Alcoholic Fatty Liver

Interventions Resveratrol placebo

Updated 5 times since 2017 Last updated: Jan 7, 2014 Started: Jun 30, 2012 Primary completion: Feb 28, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Non Alcoholic Fatty Liver, this trial is completed. The trial is conducted by Dr Azita Hekmatdoost and has accumulated 5 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr Azita Hekmatdoost

Data source: National Nutrition and Food Technology Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.